Quell Therapeutics is a London, UK based biopharmaceutical company focused on developing transformational and valued therapies for autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation, using modular engineered Treg cell therapies.

Marc Martinez-Llordella

Quell Therapeutics

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions.

Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day. 

Syncona Partners LLP

UCL Technology Fund

Fidelity

British Patient Capital

Janus Henderson Investors

Jeito Capital

Monashee Investment Management

Ridgeback Capital

Point72

Fidelity Management and Research Company

SV Health Investors

Tekla Capital Management

A big shout-out to Afrah Albadri and Maxim Smith for going above and beyond with our company values! We are very proud to have you here at Quell Tx.

We are excited to share that with Quell Therapeutics, we have won the Quris Best Partnership Alliance Award at SCRIP Awards 2023 for our recent collaboration to advance T-regulatory cell therapies in Type 1 diabetes and inflammatory bowel disease. 

This award recognises the importance of both innovative science and the strength of collaboration for pioneering next-generation medicines from the earliest stages. Our partnership continues to drive towards our ambition of cure and remission for people living with chronic immune-mediated conditions.

 #WhatScienceCanDo 

We’re delighted to have received the European Lifestars Award for Deal of the Year (>$500M) last night, for our $2+ billion partnership with AstraZeneca to develop Treg cell therapies for Type 1 Diabetes and Inflammatory Bowel Disease.
 
This award recognises the transformational value of this deal for both the company and wider industry and wouldn't have been possible without the hard work and dedication of our team. 

Congratulations also to the AstraZeneca deal team who partnered with us to get this collaboration together.

🏆 Celebrating our 2023 European Lifestars Awards Winners 🏆

Last night we proudly recognized the achievements of leaders and innovators over the last year within life sciences. We are thrilled to extend our warmest congratulations to all the winners for their outstanding contributions!

🌟 Our Esteemed Award Winners:
Seed Raise of the Year: ARTBIO
Series A Raise of the Year: Complement Therapeutics
Series B Raise of the Year: Hemab Therapeutics
Late Stage Venture Round / Series C+: Apollo Therapeutics
IPO / Listing of the Year: NewAmsterdam Pharma
Post-IPO of the Year: Bicycle Therapeutics
VC Firm of the Year: Forbion
Deal of the Year <€500m: Ariceum Therapeutics and UCB
Deal of the Year >€500m: Quell Therapeutics and AstraZeneca
M&A of the Year: GSK and Bellus Health & Novartis and Chinook Therapeutics, a Novartis Company
Pharma BD Team of the Year: Novo Nordisk
Biotech of the Year: Amolyt Pharma
Medtech of the Year: CorWave
Healthtech of the Year: Seqera
Women-Led Business of the Year: Renee Aguiar-Lucander, CEO, Calliditas Therapeutics
Private Company CEO of the Year: Cedric Ververken, CEO, Confo Therapeutics
Public Company CEO of the Year: Gunilla Osswald, CEO, BioArctic

We are proud to celebrate your accomplishments and look forward to witnessing the continued impact of your work.

Congratulations to all our winners 

#EuropeanLifestarsAwards 

We are delighted that our groundbreaking deal with AstraZeneca has been shortlisted for a second esteemed sector award: the @European Lifestars Awards Deal of the Year (>€500m) recognizes teams and organizations that have executed a truly transformational and high value creating deal for both the company and the wider industry.

The deal, signed in June 2023, combines the respective expertise of the Quell and AZ teams to unlock the potential of our engineered multi-modal engineered Treg cell therapy platform and develop novel treatments for Type 1 Diabetes and Inflammatory Bowel Disease.

Best of luck to all finalists.

Find out more: https://lnkd.in/djRhbbSc 

#Tregcelltherapies #Tregs #T1D #IBD #immunology #immunetolerance

Metric
Company Name	Quell Therapeutics
Symbol
MSH ID	COM:QUELL-TX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biopharmaceuticals
Country	GB
Stage	Series B
Employee Count	152
Website	quell-tx.com
LinkedIn	quell-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	381
Web Traffic Growth	-0.99
Valuation
Raised Capital	156M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:QUELL-TX

Quell Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue